# Safety and Efficacy of SDX-101 (R-Etodolac) in Combination With Chlorambucil, and That of Chlorambucil Alone, in Patients With Chronic Lymphocytic Leukemia (CLL)

> **NCT00151736** · PHASE2 · TERMINATED · sponsor: **Cephalon** · enrollment: 88 (actual)

## Conditions studied

- Chronic Lymphocytic Leukemia

## Interventions

- **DRUG:** Chlorambucil
- **DRUG:** R-etodolac + chlorambucil

## Key facts

- **NCT ID:** NCT00151736
- **Lead sponsor:** Cephalon
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2004-09
- **Primary completion:** 2006-02
- **Final completion:** 2008-02
- **Target enrollment:** 88 (ACTUAL)
- **Last updated:** 2012-06-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00151736

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00151736, "Safety and Efficacy of SDX-101 (R-Etodolac) in Combination With Chlorambucil, and That of Chlorambucil Alone, in Patients With Chronic Lymphocytic Leukemia (CLL)". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT00151736. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*